Previous multicenter trials, such as HORIZONS - AMI and EUROMAX, have demonstrated superiority of bivalirudin to heparin plus glycoprotein IIb / IIIa inhibitors (GPI), but a recent single center trial, HEAT - PPCI, demonstrated the superiority of heparin monotherapy over bivalirudin alone, with concern for an increased rate of stent thrombosis observed in bivalirudin - treated patients.
Based on results from this and
previous studies, pemetrexed and gemcitabine were included in a St. Jude - led
multicenter clinical trial of children and adolescents newly diagnosed with medulloblastoma.